Trial · NCT02434744
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
NCT02434744, Phase 2, Completed, Response Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus. Trials, record NCT02434744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02434744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
- NCT number
- NCT02434744
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 121 participants, actual
- Lead sponsor
- Response Pharmaceuticals
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- KD026, Placebo, Metformin
- First posted
- 2015-05-05
- Last updated
- 2023-11-18
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy | 12 Weeks | To assess the safety, tolerability, and efficacy (as measured by a 0.5%-1.5% decrease of HbA1c) of different dosages and dosing regimens of a combination of KD026 and metformin compared to placebo and metformin when administered for 3 months to subjects with type 2 diabetes mellitus |
| Secondary | Changes in Fasting Plasma Glucose (FPG) | 12 Weeks | To assess changes in fasting plasma glucose from baseline to Week 12 |
| Secondary | Changes in Insulin | 12 Weeks | To assess changes in insulin from baseline to Week 12 |
| Secondary | Changes in HOMA-IR | 12 Weeks | To assess changes in Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) from baseline to Week 12 |
| Secondary | Changes in Body Weight | 12 Weeks | To assess changes in body weight |
| Secondary | Changes in AUC | 12 Weeks | To assess the 6-hour time curve (AUC) for post prandial triglycerides and glucose. |
| Secondary | Changes in Lipids | 12 Weeks | To assess changes in total cholesterol, LDL-C, HDL-C, non-HDL-C, VLDL-C, and triglyceride levels |
| Secondary | Changes in Blood Pressure | 12 Weeks | To assess changes, if any, in baseline blood pressure associated with metabolic syndrome |
| Secondary | Changes in Waist Circumference | 12 Weeks | To assess changes, if any, in baseline waist circumference associated with metabolic syndrome |
| Secondary | Changes in Body Mass Index (BMI) | 12 Weeks | To assess changes, if any, in baseline measures of BMI associated with metabolic syndrome |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02434744
GET https://conductscience.org/api/trials/v1/NCT02434744/registered